CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
research
Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy
Authors
Adrianna Zeevi
Aldo Iacono
+29 more
Alin Girnita
Bhorade
Brack G. Hattler
Brock
Bruce Johnson
Calne
Cooper
Cosimi
Diana Zaldonis
Hale
Kenneth R. McCurry
Kirk
Knechtle
Krasinskas
Lechler
Marcos
Mueller
Preville
Samuel Yousem
Shahid Husain
Shapiro
Starzl
Starzl
Starzl
Thomas E. Starzl
Trulock
Walker
Wu
Yousem
Publication date
1 January 2005
Publisher
'Elsevier BV'
Doi
Cite
Abstract
Objectives: Acute and chronic rejection remain unresolved problems after lung transplantation, despite heavy multidrug immunosuppression. In turn, the strong immunosuppression has been responsible for mortality and pervasive morbidity. It also has been postulated to interdict potential mechanisms of alloengraftment. Methods: In 48 lung recipients we applied 2 therapeutic principles: (1) recipient pretreatment with antilymphoid antibody preparations (Thymoglobulin [SangStat, Fremont, Calif] or Campath [alemtuzumab; manufactured by ILEX Pharmaceuticals, LP, San Antonio, Tex; distributed by Berlex Laboratories, Richmond, Calif]) and (2) minimal posttransplant immunosuppression with tacrolimus monotherapy or near-monotherapy. Our principal analysis was of the events during the critical first 6 posttransplant months of highest immunologic and infectious disease risk. Results were compared with those of 28 historical lung recipients treated with daclizumab induction and triple immunosuppression (tacrolimus-prednisone-azathioprine). Results: Recipient pretreatment with both antilymphoid preparations allowed the use of postoperative tacrolimus monotherapy with prevention or control of acute rejection. Freedom from rejection was significantly greater with Campath than with Thymoglobulin (P = .03) or daclizumab (P = .05). After lymphoid depletion with Thymoglobulin or Campath, patient and graft survival at 6 months was 90% or greater. Patient and graft survival after 9 to 24 months is 84.2% in the Thymoglobulin cohort, and after 10 to 12 months, it is 90% in the Campath cohort. There has been a subjective improvement in quality of life relative to our historical experience. Conclusion: Our results suggest that improvements in lung transplantation can be accomplished by altering the timing, dosage, and approach to immunosuppression in ways that might allow natural mechanisms of alloengraftment and diminish the magnitude of required maintenance immunosuppression. Copyright © 2005 by The American Association for Thoracic Surgery
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Name not available
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:d-scholarship.pitt.edu:558...
Last time updated on 23/11/2016
D-Scholarship@Pitt
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:d-scholarship.pitt.edu:558...
Last time updated on 19/07/2013
Elsevier - Publisher Connector
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 04/06/2019
Name not available
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:d-scholarship.pitt.edu:558...
Last time updated on 15/12/2016
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 17/02/2019